Silvino Di Francesco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Silvino Di Francesco has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Antonella Gallo
Department of Geriatrics, Orthopedics and Rheumatology, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, 00168 Rome, Italy
1 shared publication - Elena Verrecchia
Department of Geriatrics, Orthopaedics and Rheumatology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
1 shared publication - Francesco Landi
Department of Geriatrics, Orthopedics and Rheumatology, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, 00168 Rome, Italy
1 shared publication - Laura Gerardino
Department of Aging, Orthopaedic and Rheumatological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy
1 shared publication - Ludovico Luca Sicignano
Department of Geriatrics, Orthopaedics and Rheumatology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
1 shared publication - Maria Grazia Massaro
Department of Geriatrics and Orthopedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
1 shared publication
Latest Publications
- Open Access
Interleukin-1 Blockers in Recurrent and Acute Pericarditis: State of the Art and Future Directions
Diseases of the pericardium encompass a spectrum of conditions, including acute and recurrent pericarditis, where inflammation plays a pivotal role in the pathogenesis and clinical manifestations. Anti-inflammatory therapy indeed forms the cornerstone of treating these conditions: NSAIDs, colchicine, and corticosteroids (as a second-line treatment) are recommended by current guidelines. However, these medications come with several contraindications and are not devoid of adverse effects. In recent years, there has been an increased focus on the role of the inflammasome and potential therapeutic targets. Recurrent pericarditis also shares numerous characteristics with other autoinflammatory diseases, in which interleukin-1 antagonists have already been employed with good efficacy and safety. The objective of this review is to summarize the available studies on the use of anti-IL-1 drugs both in acute and recurrent pericarditis.
Open AccessInterleukin-1 Blockers in Recurrent and Acute Pericarditis: State of the Art and Future Directions
Diseases of the pericardium encompass a spectrum of conditions, including acute and recurrent pericarditis, where inflammation plays a pivotal role in the pathogenesis and clinical manifestations. Anti-inflammatory therapy indeed forms the cornerstone of treating these conditions: NSAIDs, colchicine, and corticosteroids (as a second-line treatment) are recommended by current guidelines. However, these medications come with several contraindications and are not devoid of adverse effects. In recent years, there has been an increased focus on the role of the inflammasome and potential therapeutic targets. Recurrent pericarditis also shares numerous characteristics with other autoinflammatory diseases, in which interleukin-1 antagonists have already been employed with good efficacy and safety. The objective of this review is to summarize the available studies on the use of anti-IL-1 drugs both in acute and recurrent pericarditis.